{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:02:43Z","timestamp":1790697763848,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K15767"],"award-info":[{"award-number":["JP24K15767"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Quantitative analysis of amyloid PET images is increasingly used to support visual interpretation and to provide objective measures of amyloid burden. However, quantitative values may vary depending on the analysis software used. This study aimed to evaluate the quantitative agreement between two analysis platforms, AMYclz and CortexID, for\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetapir amyloid PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 103 consecutive patients who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetapir PET for evaluation of cognitive impairment. Visual interpretation was used to classify scans as amyloid-positive or amyloid-negative. Quantitative analysis was performed using CortexID and AMYclz software to obtain global cortical standardized uptake value ratios (SUVr). AMYclz additionally provided Centiloid scale (CL) values. The ability of quantitative metrics to differentiate visually positive and negative scans was evaluated using receiver operating characteristic (ROC) analysis, and agreement between software platforms was assessed using correlation, linear regression, and Bland\u2013Altman analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 103 patients, 59 were visually classified as amyloid-positive and 44 as amyloid-negative. CortexID SUVr values were significantly higher in amyloid-positive patients than in amyloid-negative patients (1.30\u2009\u00b1\u20090.14 vs. 0.97\u2009\u00b1\u20090.09,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). AMYclz SUVr showed similar separation between groups (1.34\u2009\u00b1\u20090.14 vs. 0.99\u2009\u00b1\u20090.09,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).   ROC analysis demonstrated excellent discrimination for CortexID SUVr (AUC\u2009=\u20090.986), AMYclz SUVr (AUC\u2009=\u20090.996), and CL values (AUC\u2009=\u20090.996). CortexID and AMYclz SUVr values showed strong correlation (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.957) with minimal systematic bias. Discordant classification between the two software platforms was observed in three cases (2.9%), all near the diagnostic threshold.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      AMYclz and CortexID demonstrated excellent quantitative agreement for\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetapir amyloid PET. Both AMYclz SUVr and CL values showed excellent ability to differentiate visually amyloid-positive and amyloid-negative scans, supporting the reliability of quantitative amyloid PET analysis across different software platforms in clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-02026-1","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:42:23Z","timestamp":1780900943000},"page":"1829-1835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative agreement between AMYclz and CortexID for 18F-florbetapir amyloid PET: a retrospective study of 103 patients"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-3662","authenticated-orcid":false,"given":"Yoichi","family":"Otomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Shinya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manduukhai","family":"Badarchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nakataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuishin","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dor\u00e9 V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2018.9.","journal-title":"Nat Rev Neurol"},{"key":"2026_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u2013e15154. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"key":"2026_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"2026_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a clinical-biological construct-an international working group recommendation. JAMA Neurol. 2024;81:1304\u201311. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3770.","journal-title":"JAMA Neurol"},{"key":"2026_CR5","doi-asserted-by":"publisher","first-page":"e","DOI":"10.1016\/j.jalz.2013.01.002","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer\u2019s association. Alzheimers Dement. 2013;9:e\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2013.01.002.","journal-title":"Alzheimers Dement"},{"key":"2026_CR6","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21:e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70\u20137. https:\/\/doi.org\/10.2967\/jnumed.112.109009.","journal-title":"J Nucl Med"},{"issue":"3","key":"2026_CR8","doi-asserted-by":"publisher","first-page":"e2499","DOI":"10.1002\/brb3.2499","volume":"12","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Yamao T. Software development for quantitative analysis of brain amyloid PET. Brain Behav. 2022;12(3):e2499. https:\/\/doi.org\/10.1002\/brb3.2499.","journal-title":"Brain Behav"},{"issue":"3","key":"2026_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12149-025-02134-4","volume":"40","author":"H Yamada","year":"2026","unstructured":"Yamada H, Yokoyama K, Oyama J, Tsuchiya J, Nishida Y, Sanjyo N, et al. Comparison of MRI-, CT- and PET-based anatomical standardization for centiloid scale calculation in [18F]florbetapir positron emission tomography. Ann Nucl Med. 2026;40(3):349\u201356. https:\/\/doi.org\/10.1007\/s12149-025-02134-4.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"2026_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12149-022-01769-x","volume":"36","author":"E Imabayashi","year":"2022","unstructured":"Imabayashi E, Tamamura N, Yamaguchi Y, Kamitaka Y, Sakata M, Ishii K. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer\u2019s disease. Ann Nucl Med. 2022;36(10):865\u201375. https:\/\/doi.org\/10.1007\/s12149-022-01769-x.","journal-title":"Ann Nucl Med"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer\u2019s disease and cognitively normal subjects. J Nucl Med. 2012;53:378\u201384. https:\/\/doi.org\/10.2967\/jnumed.111.090340.","journal-title":"J Nucl Med"},{"key":"2026_CR12","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","volume":"46","author":"VL Villemagne","year":"2008","unstructured":"Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer\u2019s disease. Neuropsychologia. 2008;46:1688\u201397. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2008.02.008.","journal-title":"Neuropsychologia"},{"key":"2026_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/alzrt195","volume":"5","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, van Berckel BN. Amyloid imaging in clinical trials. Alzheimers Res Ther. 2013;5:36. https:\/\/doi.org\/10.1186\/alzrt195.","journal-title":"Alzheimers Res Ther"},{"key":"2026_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"2026_CR15","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3390\/diagnostics15162028","volume":"15","author":"M Cheon","year":"2025","unstructured":"Cheon M, Yi H, Ha SW, Kang MJ, Jeong DE, Abdelhafez YG, et al. Comparison of amyloid-PET analysis software using 18F-florbetaben PET in patients with cognitive impairment. Diagnostics (Basel). 2025;15:2028. https:\/\/doi.org\/10.3390\/diagnostics15162028.","journal-title":"Diagnostics (Basel)"},{"key":"2026_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13550-023-00994-3","volume":"13","author":"HG Pemberton","year":"2023","unstructured":"Pemberton HG, Buckley C, Battle M, Bollack A, Patel V, Tomova P, et al. Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment. EJNMMI Res. 2023;13:48. https:\/\/doi.org\/10.1186\/s13550-023-00994-3.","journal-title":"EJNMMI Res"},{"key":"2026_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/qims-21-188","volume":"12","author":"EG M\u00fcller","year":"2022","unstructured":"M\u00fcller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME. Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer\u2019s disease. Quant Imaging Med Surg. 2022;12:493\u2013509. https:\/\/doi.org\/10.21037\/qims-21-188.","journal-title":"Quant Imaging Med Surg"},{"key":"2026_CR18","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","volume":"48","author":"M Bucci","year":"2021","unstructured":"Bucci M, Savitcheva I, Farrar G, Salvad\u00f3 G, Collij L, Dor\u00e9 V, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48:2183\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05311-5.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02026-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:13:41Z","timestamp":1790694821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-02026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02026-1","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Tokushima University Hospital (Approval No. 4588). The requirement for written informed consent was waived in accordance with the institutional guidelines for retrospective studies using anonymized data, with appropriate information disclosure to the public.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}